107 related articles for article (PubMed ID: 3251899)
1. Chelator-induced enhancement of 67Ga tumour imaging: comparison of desferrioxamine with N,N'-ethylene-bis[2-hydroxy-5-carboxyphenylglycine].
Hunt FC
Int J Rad Appl Instrum B; 1988; 15(6):651-7. PubMed ID: 3251899
[TBL] [Abstract][Full Text] [Related]
2. Relative tumour enhancement of 67Ga uptake by desferrioxamine.
Hammersley PA
Eur J Nucl Med; 1984; 9(10):461-71. PubMed ID: 6595115
[TBL] [Abstract][Full Text] [Related]
3. Potential radiopharmaceuticals for the diagnosis of biliary atresia and neonatal hepatitis: EHPG and HBED chelates of 67Ga and 111In.
Hunt FC
Int J Rad Appl Instrum B; 1988; 15(6):659-64. PubMed ID: 3150845
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic enhancement of gallium-67 tumor-to-blood ratios for EMT-6 sarcoma (BALB/c mice).
Larson SM; Rasey JS; Grunbaum Z; Allen DR
Radiology; 1979 Jan; 130(1):241-4. PubMed ID: 758657
[TBL] [Abstract][Full Text] [Related]
5. Comparative studies of radiocitrates in oncological models--I. 99mTc citrate and 67Ga citrate uptake by EMT-6 tumors in mice.
Gati LJ; Wiebe LI; Tse JW; Turner CJ; Noujaim AA
Int J Rad Appl Instrum B; 1986; 13(3):253-5. PubMed ID: 3464579
[TBL] [Abstract][Full Text] [Related]
6. Deferoxamine mesylate enhancement of 67Ga tumor-to-blood ratios and tumor imaging.
Koizumi K; Tonami N; Hisada K
Eur J Nucl Med; 1982; 7(5):229-33. PubMed ID: 6954069
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for
Vugts DJ; Klaver C; Sewing C; Poot AJ; Adamzek K; Huegli S; Mari C; Visser GWM; Valverde IE; Gasser G; Mindt TL; van Dongen GAMS
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):286-295. PubMed ID: 27573793
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of iron-chelating agents in an in vivo system: potential usefulness of EHPG, a powerful iron-chelating drug.
Hershko C; Grady RW; Link G
Br J Haematol; 1982 Jun; 51(2):251-60. PubMed ID: 7082583
[TBL] [Abstract][Full Text] [Related]
9. [Enhancement of 67Ga tumor-to-blood ratios by chelating agent (author's transl)].
Saji H; Yokoyama A; Hata N; Misaki A; Tanaka H; Morita R; Fukunaga M; Torizuka K
Radioisotopes; 1980 Jan; 29(1):7-12. PubMed ID: 7375679
[TBL] [Abstract][Full Text] [Related]
10. The effect of chelating agents on the distribution of monoclonal antibodies in mice.
Ward MC; Roberts KR; Westwood JH; Coombes RC; McCready VR
J Nucl Med; 1986 Nov; 27(11):1746-50. PubMed ID: 3464701
[TBL] [Abstract][Full Text] [Related]
11. Radiolabeled porphyrin vs gallium-67 citrate for the detection of human melanoma in athymic mice.
Maric N; Chan SM; Hoffer PB; Duray P
Int J Rad Appl Instrum B; 1988; 15(5):543-51. PubMed ID: 3254877
[TBL] [Abstract][Full Text] [Related]
12. The relationship of 67Ga uptake to citrate dose, compared with 67Ga-chloride and 67Ga-transferrin in rodent tissues and tumours.
Hammersley PA; Zivanovic MA
Nuklearmedizin; 1980 Feb; 19(1):25-8. PubMed ID: 7402941
[TBL] [Abstract][Full Text] [Related]
13. Chelating agents.
Bergan T; Klaveness J; Aasen AJ
Chemotherapy; 2001; 47(1):10-4. PubMed ID: 11125227
[TBL] [Abstract][Full Text] [Related]
14. Elimination of free radionuclide by a chelating agent improves tumor-to-nontumor ratios following radioimmunotargeting with antibody labeled with 67Ga.
Ryser JE; Rose K; Jones R; Pelegrin A; Donath A; Egeli R; Smith A; Offord RE
Nucl Med Biol; 1998 Apr; 25(3):261-5. PubMed ID: 9620632
[TBL] [Abstract][Full Text] [Related]
15. The iron chelating agent, deferoxamine detoxifies Fe(Salen)-induced cytotoxicity.
Umemura M; Kim JH; Aoyama H; Hoshino Y; Fukumura H; Nakakaji R; Sato I; Ohtake M; Akimoto T; Narikawa M; Tanaka R; Fujita T; Yokoyama U; Taguri M; Okumura S; Sato M; Eguchi H; Ishikawa Y
J Pharmacol Sci; 2017 Aug; 134(4):203-210. PubMed ID: 28779994
[TBL] [Abstract][Full Text] [Related]
16. Comparative kinetic studies of simultaneously injected 167Tm- and 67Ga-citrate in normal and tumour bearing mice.
Beyer GJ; Franke WG; Hennig K; Johannsen BA; Khalkin VA; Kretzschmar M; Lebedev NA; Münze R; Novgorodov AF; Thieme K
Int J Appl Radiat Isot; 1978 Nov; 29(11):673-81. PubMed ID: 112065
[No Abstract] [Full Text] [Related]
17. Mechanisms of distribution of gallium 67 in mouse tumour hosts.
Sephton RG; De Abrew S; Hodgson GS
Br J Radiol; 1982 Feb; 55(650):134-41. PubMed ID: 7055660
[TBL] [Abstract][Full Text] [Related]
18. A newly designed radioimmunoconjugate releasing a hippurate-like radiometal chelate for enhanced target/non-target radioactivity.
Arano Y; Matsushima H; Tagawa M; Inoue T; Koizumi M; Hosono M; Sakahara H; Endo K; Konishi J; Yokoyama A
Nucl Med Biol; 1994 Jan; 21(1):63-9. PubMed ID: 9234265
[TBL] [Abstract][Full Text] [Related]
19. Investigation of physicochemical and in-vivo behavior of diastereomeric iron-59, gallium-68, and indium-111-EHPG trivalent metal complexes.
Madsen SL; Bannochie CJ; Martell AE; Mathias CJ; Welch MJ
J Nucl Med; 1990 Oct; 31(10):1662-8. PubMed ID: 2213190
[TBL] [Abstract][Full Text] [Related]
20. The biodistribution of 67Ga-labelled N-hydroxyamino acid derivatives in tumour-bearing rats.
Herscheid JD; Knops GH; Hoekstra M
Nucl Med Commun; 1986 Jan; 7(1):53-7. PubMed ID: 3459111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
